drugset
drugset / Trial / NCT05579925

A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis

NCT05579925 ↗

Phase 2 Completed 24 enrolled Keymed Biosciences Co.Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, single arm, open-label study to evaluate safety and primary efficacy in children patients with moderate-to severe atopic dermatis.

Timeline

Start
2022-10-07
Primary completion
2023-07-28
Completion
2023-07-28

Drugs

EvaluationDrugModalityDoseRoute
Subject CM310 Monoclonal antibody 300 mg Subcutaneous
Subject CM310 Monoclonal antibody 600 mg Subcutaneous

Indications

atopic eczema